Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Publication Date timeline is not available.
Page 1
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.
Pharmacogenomics J. 2008 Jun;8(3):186-95. doi: 10.1038/sj.tpj.6500458. Epub 2007 May 15.
Pharmacogenomics J. 2008.
PMID: 17505501
Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.
Wåhlander K, Eriksson H, Lundström T, Billing Clason S, Wall U, Nyström P, Wessman P, Schulman S; THRIVE III Investigators.
Wåhlander K, et al.
Br J Haematol. 2006 Apr;133(1):68-77. doi: 10.1111/j.1365-2141.2006.05960.x.
Br J Haematol. 2006.
PMID: 16512831
Free article.
Item in Clipboard
Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study.
Schulman S, Lundström T, Wålander K, Billing Clason S, Eriksson H.
Schulman S, et al.
Thromb Haemost. 2005 Oct;94(4):820-4.
Thromb Haemost. 2005.
PMID: 16270637
Clinical Trial.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.